Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
This trial is active, not recruiting.
|Sponsor||University of North Carolina, Chapel Hill|
|Collaborator||Merck Sharp & Dohme Corp.|
|Start date||December 2011|
|End date||December 2015|
|Trial size||60 participants|
|Trial identifier||NCT01949077, 11-2124|
The purpose of the study is to determine differences in levels of serum chemokines from patients undergoing treatment with Boceprevir. The aim is to determine if non-responders have significantly different levels of chemokines than responders.
Level (ng/mL) of serum chemokines.
time frame: Baseline: <=6 months prior to start of treatment and Post-treatment: <=6-months after the last dose
Male or female participants at least 18 years old.
Inclusion Criteria: - All adult patients (age 18 or older) treated with an antiviral Hepatitis C treatment regimen that includes Boceprevir. Exclusion Criteria: - Inability to provide informed consent for a serum sample enrolled in the University of North Carolina Liver Center serum bank. - No pre and post serum sample available within 6 months of the treatment period.
|Official title||Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|
|Principal investigator||Michael W Fried, MD|
|Description||Patients undergoing standard of care at the UNC Liver Center are consented for collection of an additional serum sample under the UNC Liver Center serum and tissue bank study. These samples will be used to analyze differences in serum chemokines across responders and non-responders.|
Call for more information